Milvexian did not lower risk for CV death, MI or ischemic stroke. No excess bleeding risk was reported. MUNICH — Milvexian ...
Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting ...
Statin therapy cut risk for major adverse CV events by 30% for healthy older adults compared with placebo, but did not extend disability-free survival, according to data presented at the European ...
Myocardial infarctions will now fall under one of three clinical categories as part of a simplified universal definition, a ...
The FDA has approved tirzepatide for reduction of cardiovascular risk in adults with type 2 diabetes, Eli Lilly ...
The United States’ death rate likely dropped to a record low last year, according to provisional CDC data.The National Center ...
The FDA approved an updated round of COVD-19 vaccines for the 2026-2027 respiratory disease season that target circulating ...
In patients with left-sided infective endocarditis, a response-tailored antibiotic strategy conferred more time alive without ...
E-scooters are popular for recreation and transportation, with ride-share options available in 133 cities across the United ...
In patients with symptomatic nonobstructive hypertrophic cardiomyopathy, aficamten led to greater improvements in health ...
Newer IOL power calculations have good accuracy in eyes with intentional myopic targets, according to a study published in ...
Pseudophakic patients with glaucoma who aren’t doing well on their drops or who are progressing despite reasonable adherence ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results